Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review)
- Authors:
- Mário Fontes‑Sousa
- Maria Amorim
- Sofia Salta
- Susana Palma De Sousa
- Rui Henrique
- Carmen Jerónimo
-
Affiliations: Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI‑IPOP), Portuguese Oncology Institute of Porto (IPOPorto) 4200‑072 Porto, Portugal, Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOPorto) 4200‑072 Porto, Portugal - Published online on: January 11, 2019 https://doi.org/10.3892/or.2019.6967
- Pages: 1431-1438
This article is mentioned in:
Abstract
Magnani L, Brunelle M, Gévry N and Lupien M: Chromatin landscape and endocrine response in breast cancer. Epigenomics. 4:675–683. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cheang MC, van de Rijn M and Nielsen TO: Gene expression profiling of breast cancer. Annu Rev Pathol. 3:67–97. 2008. View Article : Google Scholar : PubMed/NCBI | |
Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A and Perrone F; NCI-Naple Breast Cancer Group, : Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, et al: 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 31:244–259. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rodríguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med. 17:330–339. 2011. View Article : Google Scholar : PubMed/NCBI | |
Jones PA: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet. 13:484–492. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bannister AJ and Kouzarides T: Regulation of chromatin by histone modifications. Cell Res. 21:381–395. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zentner GE and Henikoff S: Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol. 20:259–266. 2013. View Article : Google Scholar : PubMed/NCBI | |
Amorim M, Salta S, Henrique R and Jerónimo C: Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med. 14:2652016. View Article : Google Scholar : PubMed/NCBI | |
Kung JT, Colognori D and Lee JT: Long noncoding RNAs: Past, present, and future. Genetics. 193:651–669. 2013. View Article : Google Scholar : PubMed/NCBI | |
Huntzinger E and Izaurralde E: Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR and Davidson NE: Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor α (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol. 19:1740–1751. 2005. View Article : Google Scholar : PubMed/NCBI | |
Heyn H and Esteller M: DNA methylation profiling in the clinic: Applications and challenges. Nat Rev Genet. 13:679–692. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jerónimo C and Henrique R: Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett. 342:264–274. 2014. View Article : Google Scholar : PubMed/NCBI | |
Costa-Pinheiro P, Montezuma D, Henrique R and Jerónimo C: Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 7:1003–1015. 2015. View Article : Google Scholar : PubMed/NCBI | |
Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI | |
Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006. View Article : Google Scholar : PubMed/NCBI | |
Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI | |
Stone A, Zotenko E, Locke WJ, Korbie D, Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA, et al: DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 6:77582015. View Article : Google Scholar : PubMed/NCBI | |
Williams KE, Anderton DL, Lee MP, Pentecost BT and Arcaro KF: High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines. Epigenetics. 9:297–307. 2014. View Article : Google Scholar : PubMed/NCBI | |
Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, et al: European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients: Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer. 43:1679–1686. 2007. View Article : Google Scholar : PubMed/NCBI | |
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, et al: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol. 26:5036–5042. 2008. View Article : Google Scholar : PubMed/NCBI | |
Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D and Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 283:31079–31086. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI | |
Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI | |
He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R and Tang JH: miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp Ther Med. 5:813–818. 2013. View Article : Google Scholar : PubMed/NCBI | |
Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI | |
ClinicalTrials.gov: MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer. ClinicalTrials.gov2016. https://clinicaltrials.gov/ct2/show/NCT01231386 | |
ClinicalTrials.gov: Circulating miRNAs. ICORG 10–11, V2. ClinicalTrials.gov2017. https://clinicaltrials.gov/ct2/show/NCT01722851 | |
ClinicalTrials.gov: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (MIRHO). ClinicalTrials.gov. 2014, https://clinicaltrials.gov/ct2/show/NCT01612871 | |
Meijer D, van Agthoven T, Bosma PT, Nooter K and Dorssers LC: Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 4:379–386. 2006. View Article : Google Scholar : PubMed/NCBI | |
Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC and Van Agthoven T: Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer. 103:1284–1291. 2010. View Article : Google Scholar : PubMed/NCBI | |
Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al: The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 7:127912016. View Article : Google Scholar : PubMed/NCBI | |
Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, Gyorffy B and Lupien M: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA. 110:E1490–E1499. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Duan Z, Nugent Z, Zou JX, Borowsky AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, et al: Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 378:69–79. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jansen MP, Knijnenburg T, Reijm EA, Simon I, Kerkhoven R, Droog M, Velds A, van Laere S, Dirix L, Alexi X, et al: Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. Cancer Res. 73:6632–6641. 2013. View Article : Google Scholar : PubMed/NCBI | |
Légaré S and Basik M: Minireview: The link between ERα corepressors and histone deacetylases in tamoxifen resistance in breast cancer. Mol Endocrinol. 30:965–976. 2016. View Article : Google Scholar : PubMed/NCBI | |
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 104:1828–1835. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ and Trepel JB: Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 31:2128–2135. 2013. View Article : Google Scholar : PubMed/NCBI | |
Raha P, Thomas S, Thurn KT, Park J and Munster PN: Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 17:262015. View Article : Google Scholar : PubMed/NCBI | |
Gévry N, Hardy S, Jacques P-É, Laflamme L, Svotelis A, Robert F and Gaudreau L: Histone H2A.Z is essential for estrogen receptor signaling. Genes Dev. 23:1522–1533. 2009. View Article : Google Scholar : PubMed/NCBI | |
Svotelis A, Gévry N, Grondin G and Gaudreau L: H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle. 9:364–370. 2010. View Article : Google Scholar : PubMed/NCBI | |
Nayak SR, Harrington E, Boone D, Hartmaier R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanfilippo J, Davidson NE, et al: A role for histone H2B variants in endocrine-resistant breast cancer. Horm Cancer. 6:214–224. 2015. View Article : Google Scholar : PubMed/NCBI | |
Magnani L, Ballantyne EB, Zhang X and Lupien M: PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. PLoS Genet. 7:e10023682011. View Article : Google Scholar : PubMed/NCBI | |
Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, Ahn SG, Yoon JH and Kang KW: Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 130:73–83. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hiken JF, McDonald JI, Decker KF, Sanchez C, Hoog J, VanderKraats ND, Jung KL, Akinhanmi M, Rois LE, Ellis MJ, et al: Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer. Oncogene. 36:2319–2327. 2017. View Article : Google Scholar : PubMed/NCBI | |
Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A: Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 13:91–104. 2008. View Article : Google Scholar : PubMed/NCBI | |
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, et al: Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 6:229ra412014. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Zhang B, Fang J and Cao X: Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. Int J Clin Exp Pathol. 8:9500–9505. 2015.PubMed/NCBI | |
Kim SJ, Kang HS, Jung SY, Min SY, Lee S, Kim SW, Kwon Y, Lee KS, Shin KH and Ro J: Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med. 88:1123–1131. 2010. View Article : Google Scholar : PubMed/NCBI | |
Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, et al: DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 111:429–437. 2008. View Article : Google Scholar : PubMed/NCBI | |
Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP and Oesterreich S: Progesterone receptor isoform-specific promoter methylation: Association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 17:4177–4186. 2011. View Article : Google Scholar : PubMed/NCBI | |
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene. 34:3895–3907. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lü M, Ding K, Zhang G, Yin M, Yao G, Tian H, Lian J, Liu L, Liang M, Zhu T, et al: MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ. Sci Rep. 4:87352015. View Article : Google Scholar | |
Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z and Xiao GG: let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Mol Med. 17:1233–1241. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bergamaschi A and Katzenellenbogen BS: Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene. 31:39–47. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, Zhao Q, Ren T, Ju X, Gutman E, et al: miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget. 5:1083–1090. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chen MJ, Cheng YM, Chen CC, Chen YC and Shen CJ: MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun. 483:840–846. 2017. View Article : Google Scholar : PubMed/NCBI | |
Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 8:e623342013. View Article : Google Scholar : PubMed/NCBI | |
Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME and Jones FE: Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 31:2049–2057. 2010. View Article : Google Scholar : PubMed/NCBI | |
Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, et al: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 133:937–947. 2012. View Article : Google Scholar : PubMed/NCBI | |
Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW and Foekens JA: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 127:43–51. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W and Brauch H: Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer. 49:3598–3608. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB and Sarkar FH: Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through downregulation of HDAC4. BMC Cancer. 15:5402015. View Article : Google Scholar : PubMed/NCBI | |
Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L and Zhang J: Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 147:423–431. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shen R, Wang Y, Wang CX, Yin M, Liu HL, Chen JP, Han JQ and Wang WB: MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 7:2115–2126. 2015.PubMed/NCBI | |
Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, et al: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One. 6:e209802011. View Article : Google Scholar : PubMed/NCBI | |
Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS, Yiu CC, Loo TY, Nakamura Y, Akahira J, Ishida T, et al: Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol. 227:357–366. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bailey ST, Westerling T and Brown M: Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res. 75:436–445. 2015. View Article : Google Scholar : PubMed/NCBI | |
Masri S, Liu Z, Phung S, Wang E, Yuan YC and Chen S: The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 124:89–99. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hayes EL and Lewis-Wambi JS: Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA. Breast Cancer Res. 17:402015. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S and Iwase H: HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 10:6962–6968. 2004. View Article : Google Scholar : PubMed/NCBI | |
Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, et al: Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 24:4531–4539. 2005. View Article : Google Scholar : PubMed/NCBI | |
Svotelis A, Bianco S, Madore J, Huppé G, Nordell-Markovits A, Mes-Masson AM and Gévry N: H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J. 30:3947–3961. 2011. View Article : Google Scholar : PubMed/NCBI |